Drug intelligence / Profile preview

NaHao

Development stage: Preclinical
Lead developer: Affiliated Cancer Hospital of Nanjing Medical University
Administration: Oral, Topical

Overview

NaHao is an oral antibacterial nursing solution and spray developed for the management of oral mucositis and acute skin injury. It is specifically indicated for conditions caused by tumor radiotherapy and chemotherapy, aiming to relieve and prevent these complications through its antibacterial properties. Clinical observations have been conducted by institutions such as Jiangsu Cancer Hospital and China Pharmaceutical University to assess its efficacy and safety.

Brand names: NaHaoNahao SprayNaHao oral antibacterial nursing solution
Other names: 纳好口腔抗菌护理液

Beyond the preview

Go deeper on NaHao.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NaHao.